Abbvie – Myelofibrosis – M16 -191

People with Myelofibrosis are asked to participate in a research study being conducted by Monter Cancer Center.

You may be eligible to participate in this study if you:

• Are a male or female at least 18 years of age
• Have adequate bone marrow reserve
• Have adequate renal & hepatic function and enzymes

You may NOT participate in this study if you:

• Subjects must meet all of the criteria in the protocol in order to be included in the study. Anything other than a positive response to the questions in the protocol will result in exclusion from study participation.

Contact Information
Carolyn Pellizzari,Study Coordinator
450 Lakeville Road Lake Success, New York 11042
Email: cpellizzar@northwell.edu
Telephone: (516) 734-8921

Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.

You may be eligible to participate in this study if you:

• Are a male or female at least 18 years of age
• Have a diagnosis of PMF, PPV-MF, or PET-MF
• Have DIPSS risk category of intermediate-1, intermediate-2, or high
• Have been treated with ruxolitinib for ≥ 3 months with a stable dose for at least the last 8 weeks

You may NOT participate in this study if you:

• Have received prior therapy with any drug that inhibits PI3K
• Have recent history of inadequate bone marrow reserve
• Have inadequate liver or renal function
• Have uncontrolled, severe, or unstable cardiac disease
• Have known immunodeficiency virus (HIV) infection
• Have an active bacterial, fungal, parasitic, or viral infection
• Are pregnant or breastfeeding

Contact Information
Hieu Liem Nguyen, Study Coordinator
1300 Morris Park Ave, Ullmann Building Rm 921
Bronx, NY 10461Phone: (718) 325-9392
Email: hinguyen@montefiore.org